Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tremelimumab and Durvalumab for MSI-High Resectable Gastric or Gastroesophageal Junction Cancer (INFINITY)
NCT04817826Phase 2Active, not recruiting
- Sponsor
- Gruppo Oncologico Nord Ovest
- Start
- Apr 2021
- Primary completion
- Feb 2026
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of tremelimumab, durvalumab in gastric cancer (GC), gastroesophageal junction cancer, sponsored by Gruppo Oncologico Nord Ovest. Started Apr 2021; status: active, not recruiting.
02
Drugs
tremelimumabdurvalumab
03
Conditions
gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT04817826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04817826.